Navigation Links
InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
Date:4/1/2008

ted by Roche.

Regarding formulation, InterMune reported that Roche has completed development of the tablet formulation of ITMN-191 that will be used in the Phase 2 program. Given the relatively low total daily dose of ITMN-191 required to show substantial antiviral activity, Roche has begun work on a modified-release formulation of ITMN-191 with the goal of optimizing the delivery of ITMN-191, potentially to a once per day administration.

Phase 1b (MAD) Trial Design

The ongoing Phase 1b placebo-controlled study is designed to assess the effect of multiple doses of ITMN-191 given as monotherapy on viral kinetics, viral resistance, pharmacokinetics, safety and tolerability. A principal goal of the MAD study is to help choose the range of doses of ITMN-191 that when administered in combination with Pegasys(R) (pegylated interferon alfa-2a) and Copegus(R) (ribavirin) would likely offer the optimal protease inhibitor-based triple combination regimen in terms of efficacy, safety and tolerability. The Phase 1b study also will inform the design of future combination studies using small molecule HCV compounds of different mechanisms of action.

In the Phase 1b study, four cohorts of treatment-nave patients received ITMN-191 in a gelatin capsule every 12 hours or every 8 hours with food for a period of 14 days. In addition, a single cohort of treatment-experienced chronic hepatitis C patients infected with HCV genotype 1 will begin dosing next week at the 300mg every 12 hour dose level.

Conference Call and Webcast Details

InterMune will host a conference call today at 8:30 a.m. EDT to discuss the preliminary Phase 1b clinical trial results of ITMN-191 and the Program Update. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID #41908166. A replay of the webcast and teleconference will be available approximately three hours after the call. '/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune Announces Start of Phase 1b Trial of ITMN-191
2. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
3. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
4. Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers
5. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
8. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
11. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Calif., Oct. 21, 2014 Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... Second quarter overview: , Revenues of $53.9 ... , Diluted EPS of $0.24, up 33% over last ... Service revenues from Abaxis Veterinary Reference Laboratories (AVRL) of ...
(Date:10/22/2014)... 22, 2014 Sanomedics International Holdings, Inc. (OTCQB: ... Global Research & Data Services, demand for thermometers is ... through 2018, as demand for more accurate digital thermometers ... the world,s largest market for thermometers, and one of ... Sanomedics International Holdings, Inc. Sanomedics International Holdings ...
(Date:10/22/2014)... 22, 2014  AcelRx Pharmaceuticals, Inc. (NASDAQ: ... the  IAP310 study have been published in ... peer-reviewed journal with broad, multidisciplinary readership. IAP310 was ... safety and efficacy of Zalviso, also referred to ... the treatment of post-operative pain in patients following ...
Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2
... Innocoll, Inc., a privately-held,biopharmaceutical company, announced ... clinical trials sponsored by its wholly owned ... TOPICAL for the,treatment and prevention of infected ... TOPICAL is a biodegradable and fully resorbable,Gentamicin-Collagen ...
... WALTHAM, Mass., April 16 Repligen Corporation,(Nasdaq: ... and Drug Administration,(FDA) has granted Fast Track designation ... to improve the assessment of pancreatic,duct structures by ... designed to facilitate the development and expedite the ...
Cached Medicine Technology:Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 4Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging 2Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging 3Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging 4
(Date:10/22/2014)... Brownsville, TX (PRWEB) October 22, 2014 On ... will present its fourth annual family health and fitness fair ... Hispanic family physical activity and good nutrition for better health ... This event, which is free and open to the public, ... Street, in Brownsville, from 9:00 am to 1:00 pm. ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... three Ebola cases in Dallas. But, mental health specialists say ... President Barack Obama on Friday appointed an Ebola "czar" ... infected two Dallas nurses who cared for a Liberian man ... Hospital. But the U.S. cases are miniscule in the ...
(Date:10/22/2014)... Washington, D.C. (PRWEB) October 22, 2014 With ... November, a national survey by the American Institutes for Research ... they know how to use health insurance, but 42 percent ... review a plan’s details before signing up for coverage. , ... literacy, with only 20 percent able to calculate correctly how ...
(Date:10/22/2014)... 22, 2014 Although there are only 24 hours ... many people who have trouble finding time within their busy schedules ... for long periods of time to get in shape. Here are ... on the go. , Change Up Your Commute , Consider ... to add some exercise into your daily routine. If you must ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... women undergoing in vitro fertilization (IVF) are only about half ... popular assisted reproduction technique, new research indicates, and the racial ... the study, about 31 percent of white patients became pregnant ... Analyzing more than 4,000 IVF cycles over two years ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
... , MONDAY, Oct. 31 (HealthDay News) -- Jay Cuetara arrived ... was told a critical component of the chemo cocktail that ... was unavailable. Cuetara, 49, didn,t get treatment that ... His San Francisco hospital managed to procure the drug and ...
... scientists report that patients whose estrogen receptor (ER)-positive breast ... factor experience poor outcomes -- including increased mortality. The ... levels of this factor, the protein known as heat ... more aggressive than those with low levels. ...
... likely to be divorced, are cleverer and feel better, reveals a ... today with 30 years ago. "It,s time to start talking about ... number of elderly is rising worldwide, and it is estimated that ... of the century. At the same time, old age ...
... scientists at Tufts University will develop ultra-sensitive techniques at ... cancer earlier, and treat it with greater precision, through ... Defense Breast Cancer Research Program made to Tufts chemist ... provide "individuals who have a history of creativity, innovative ...
... FRANCISCO -- Birds are getting bigger in central California, and ... colleagues. Goodman uncovered the trend while working as a ... analyzing data from thousands of birds caught and released each ... Point Reyes National Seashore. The SF State scientists, working ...
... -- Doctors who listen to Mozart while performing colonoscopies ... Better detection of these so-called adenomatous polyps could save ... colorectal cancer are better than 90 percent if the ... that Mozart,s music can provide a significant short-term boost ...
Cached Medicine News:Health News:Obama Acts to Ease U.S. Drug Shortages 2Health News:Obama Acts to Ease U.S. Drug Shortages 3Health News:High levels of master heat shock protein linked to poor prognosis in breast cancer patients 2Health News:The new old age - today's pensioners are very different to yesterday's 2Health News:Fighting breast cancer early, one cell at a time 2Health News:Bigger birds in central California, courtesy of global climate change 2Health News:Bigger birds in central California, courtesy of global climate change 3Health News:Could Listening to Mozart Help Doctors Spot Colon Polyps? 2
... DataMate system provides the ... wristband and label. Featuring ... for superior label adhesion, ... are durable and strong, ...
... PDCs computer-generated Thermal Printing Wristbands ... through direct thermal and thermal transfer ... to activate a heat-sensitive thermal coating ... transfer printers use heat to transfer ...
... Thermal Printing Wristbands and Tags print ... and thermal transfer printers. Direct thermal ... heat-sensitive thermal coating under the bands ... heat to transfer highly durable ink ...
... in settings where a more secure band is desired ... difficult to remove wristband is appropriate. The design allows ... One band to be placed on the wrist and ... first need to be replaced. This is particularly useful ...
Medicine Products: